- Home
- HSLV vs QURE Comparison
HSLV vs QURE Comparison
Compare HSLV & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSLV | QURE |
|---|---|---|
| Founded | N/A | 1998 |
| Country | Canada | Netherlands |
| Employees | 51 | 248 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | HSLV | QURE |
|---|---|---|
| Price | $5.87 | $17.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 208.9K | ★ 1.3M |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | $37.60 | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.72 | $8.73 |
| 52 Week High | $6.77 | $71.50 |
Technical Indicators
Market Signals| Indicator | HSLV | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 54.32 |
| Support Level | $4.72 | $13.47 |
| Resistance Level | $6.00 | $18.58 |
| Average True Range (ATR) | 0.35 | 1.30 |
| MACD | -0.04 | 0.17 |
| Stochastic Oscillator | 14.29 | 79.07 |
Price Performance
Historical ComparisonAbout HSLV Highlander Silver Corp. Common Shares
Highlander Silver Corp. is a mineral exploration company engaged in the acquisition, exploration and evaluation of mineral properties located in Peru. It is focused on advancing the bonanza grade San Luis gold-silver project that is located in Central Peru. The company has determined that it has one operating segment, being the exploration of mineral properties.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.